Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of KHK4083 in Healthy Adults and Ulcerative Colitis
NCT02985593Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of rocatinlimab in ulcerative colitis (UC) (3 arms), sponsored by Kyowa Kirin. Primary endpoint: Treatment-Emergent Adverse Events at 22 weeks. Started Dec 2016; status: completed.
02
Drugs
rocatinlimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02985593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985593.